title: [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
abstract: OBJECTIVE
  To analyze the expression of DD3 mRNA in the prostate tissues.
  
  
  METHODS
  DD3 mRNA was detected by realtime fluorescent quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) based on the Taqman technique in the tissues of 27 patients with non-prostate cancer( NPCa), 21 prostate cancer( PCa), 39 benign prostatic hyperplasia (BPH) and 15 normal prostate (NP). The ROC curve was used to evaluate the diagnostic value of DD3 mRNA.
  
  
  RESULTS
  DD3 mRNA expression was not detected in the NPCa tissues. The median expressions of DD3 mRNA in PCa, BPH and NP tissues were 7. 2 x 10(6), 2. 5 x 10(4) and 1.5 x 10(4) copies/mg tissue, respectively. The DD3 mRNA expression levels were significantly different between nonmalignant and malignant tissues (P < 0.01). No significant differences in DD3 mRNA expression were detected between the NP and BPH tissues and no significant correlation was found between the DD3 mRNA expression and clinical pathological parameters. The AUC-ROC was 0.937 (95% CI: 0.879 - 0.995) at cutoff value 1.4 x 10(5) copies/mg tissue. The sensitivity, specificity, accuracy, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio for DD3 were 90.5%, 85.0%, 86.7%, 76.0%, 94.3%, 6.03 and 0.11 respectively.
  
  
  CONCLUSIONS
  The DD3 mRNA expression is confined to prostate tissues and highly upregulated in PCa tissues. It has a potential application value in the early diagnosis of prostate cancer and the follow-up of the patient.
authors.affiliation: Department of Clinical Laboratory Medicine, First Affiliated Hospital of Wenzhou Medical College, Zhejiang, China. wwwtzh@wz.zj.cn
authors.forename: Zhi-hua
authors.initials: ZH
authors.lastname: Tao
authors.forename: Xiao-lu
authors.initials: XL
authors.lastname: Mao
authors.forename: Cai-hong
authors.initials: CH
authors.lastname: Wang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Chen
authors.forename: Kai-yuan
authors.initials: KY
authors.lastname: Yu
authors.forename: Zhi-liang
authors.initials: ZL
authors.lastname: Weng
authors.forename: Yuan-ping
authors.initials: YP
authors.lastname: Hu
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Xie
authors.forename: Ou-chen
authors.initials: OC
authors.lastname: Wang
authors.forename: Qi-tong
authors.initials: QT
authors.lastname: Song
authors.forename: Cheng-di
authors.initials: CD
authors.lastname: Li
authors.forename: Zhan-guo
authors.initials: ZG
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000951:Antigens, Neoplasm; D012333:RNA, Messenger; C479341:prostate cancer antigen 3, human